The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.
Many factors influence the effectiveness of contraceptive methods. Oral contraceptives are the second most popular contraceptive method after female sterilization in the US. A total of 25% of women do not use their oral contraceptives correctly; 30% of women do not use them consistently. Several new contraceptive methods with alternate routes of delivery and less frequent dosing are available. The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring is marketed under the name of NuvaRing. This is the only contraceptive ring approved by the FDA. The administration of steroids by the vaginal route may offer many advantages. Because of less frequent dosing, self-administration, and possibly, an improved side effect profile, the ring has the potential to increase successful use.
University of Montréal, Department of Obstetrics and Gynecology, St. Justine Hospital, 3175 Chemin Côte-Ste-Catherine, Montréal, QC, Canada. marie-soleil.wagner.hsj@ssss.gouv.qc.ca
Marie-Soleil
MS
Wagner
Raquel D
RD
Arias
Deborah L
DL
Nucatola
D000818:Animals; D003267:Contraception / Q000379:methods; D003274:Contraceptive Devices, Female; D017135:Desogestrel / Q000008:administration & dosage* / Q000097:blood; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans
D004338:Drug Combinations; C044815:etonogestrel; D004997:Ethinyl Estradiol; D017135:Desogestrel